Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INC1 and INC2 compounds in a psoriasis transplant model
NL-OMON45789Active, not recruiting
- Sponsor
- Derphartox
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Trial of 5-iodoindirubin-3'-monoxime in psoriasis (2 arms), sponsored by Derphartox. Primary endpoint: Effect on typical psoriasis skin features. Started Feb 2019; status: active, not recruiting.
02
Drugs
5-iodoindirubin-3'-monoxime
03
Conditions
psoriasis
Beyond the preview
Go deeper on NL-OMON45789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45789.